OCM
TGTX icon

Occam Crest Management’s TG Therapeutics TGTX Stock Holding History

Occam Crest Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.7M Sell
425,000
-152,000
-26% -$6.22M 11.8% 1
2026
Q1 		$19.2M Buy
577,000
+175,405
+44% +$5.23M 11.63% 1
2025
Q4 		$12M Sell
401,595
-8,000
-2% -$261K 8.31% 4
2025
Q3 		$14.8M Buy
+409,595
New +$13.5M 9% 3

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Occam Crest Management's TGTX Position: Q2 2026 in Review

Occam Crest Management reduced its TG Therapeutics (TGTX) stake by 26% in Q2 2026, selling an estimated $6.22M and leaving 425,000 shares worth $22.7M. The position accounts for 11.8% of the portfolio, ranked #1.

Occam Crest Management first reported a position in TGTX in Q3 2025 and has held it in 4 quarters since. 428 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Occam Crest Management held 425,000 shares of TG Therapeutics worth $22.7M as of Q2 2026.
  • Occam Crest Management sold 152,000 TG Therapeutics shares in Q2 2026, an estimated $6.22M.
  • TG Therapeutics made up 11.8% of Occam Crest Management's portfolio in Q2 2026, its #1 holding.
  • Occam Crest Management first reported a position in TG Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 428 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Occam Crest Management's 13F filing for Q2 2026, filed 14 Aug 2026.